Amneal launches generic Welchol
Amneal on Thursday launched its generic Welchol (colesevelam HCI), a move that immediately followed the generic’s approval by the Food and Drug Administration. Amneal said that its launch makes it first to market with the generic of the treatment for hyperlipidemia, as well as Type 2 diabetes as an adjunct to diet and exercise.
"We are pleased to be one of the first companies to receive approval and launch a generic version of Welchol,” said Rob Stewart, president and CEO of Amneal. “The immediate launch of this product further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option.”
Amneal’s generic Welchol will be available in 625-mg dosage strength tablets. The drug had a U.S. market size of roughly $526 million for the 12 months ended February 2018.
"We are pleased to be one of the first companies to receive approval and launch a generic version of Welchol,” said Rob Stewart, president and CEO of Amneal. “The immediate launch of this product further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option.”
Amneal’s generic Welchol will be available in 625-mg dosage strength tablets. The drug had a U.S. market size of roughly $526 million for the 12 months ended February 2018.